drugset / Trial / NCT04142125

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

NCT04142125

Phase 3 Completed 101 enrolled Population Health Research Institute
RandomizedParallel-groupSingle-blindTreatment

Summary

CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban + aspirin or aspirin alone.

Timeline

Start
2020-02-03
Primary completion
2023-09-18
Completion
2023-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 2.5 mg Oral
Background Acetylsalicyclic acid Unknown 81 mg